Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Scientific Reports|December 19, 2018
The deubiquitylating enzyme UCHL3 regulates Ku80 retention at sites of DNA damageRyotaro Nishi, Paul W G Wijnhoven, Yusuke Kimura, et al.Cancers|January 28, 2026
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy ResistanceElsa Irving, Alaide Morcavallo, Jekaterina Vohhodina-Tretjakova, et al.Cancer Research|January 26, 2022
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor OlaparibZena Wilson, Rajesh Odedra, Yann Wallez, et al.Molecular Cancer Therapeutics|June 23, 2021
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical DevelopmentSonja J Gill, Paul W G Wijnhoven, Jacqueline H L Fok, et al.Oncogene|May 24, 2020
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cellsRebecca L Lloyd, Paul W G Wijnhoven, Antonio Ramos-Montoya, et al.Nucleic Acids Research|December 29, 2025
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cellsJonathan Ribeiro, Kjetil Hansen, Lotte van Beek, et al.Nature Communications|August 17, 2023
C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruptionAbhishek Bharadwaj Sharma, Muhammad Khairul Ramlee, Joel Kosmin, et al.Genes & Development|November 1, 2016
Synthetic lethality between PAXX and XLF in mammalian developmentGabriel Balmus, Ana C Barros, Paul W G Wijnhoven, et al.Nature Medicine|July 5, 2016
p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivityCarmen Adriaens, Laura Standaert, Jasmine Barra, et al.Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.Pageof 2